TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05570695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention right training, ARTNF
Description: In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention left training, ALTNF
Description: In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham attention right training, ARTsham
Description: During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham attention left training, ALTsham
Description: During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
Study: NCT06114797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chamomile
Description: * Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline mouthwash
Description: Saline mouthwash was used by elderly patients in the control arm.
Study: NCT06121713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GCE + Low ALA
Description: Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GCE + High ALA
Description: Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
Study: NCT04979078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Description: Patients will receive PBM on the sole of their feet and palms of their hands
Study: NCT06495008

Intervention type: OTHER
Intervention: no intervention, only questionnaires, saliva collection and taste/smell tests
Description: no intervention, only questionnaires, saliva collection and taste/smell tests

Intervention type: OTHER
Intervention: no intervention, only questionnaires, saliva collection and taste/smell tests
Description: no intervention, only questionnaires, saliva collection and taste/smell tests
Study: NCT05827965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and drug adjustement
Description: education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
Study: NCT05377177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Theta Burst Stimulation
Description: B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Theta Burst Stimulation
Description: B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
Study: NCT06299202

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: * Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy.
Study: NCT05779657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
Study: NCT06344988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise program
Description: The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Online education presentation
Description: This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online education presentation
Description: This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
Study: NCT05779657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
Study: NCT06344988

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart band
Description: Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart band
Description: Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
Study: NCT05779657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
Study: NCT06358898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dCBT-I
Description: This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mood enhanced CBT-I (M-dCBT-I)
Description: Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
Study: NCT06279221

Intervention type: DRUG
Intervention: LITFULO
Description: as provided in real world practice
Study: NCT06635005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive the Low-EDIH dietary pattern intervention
Study: NCT04896723

Intervention type: DIAGNOSTIC_TEST
Intervention: Sexual function questionnaire
Description: Sexual function questionnaire and cognitive screening assessments

Intervention type: DIAGNOSTIC_TEST
Intervention: Sexual function questionnaire
Description: Sexual function questionnaire and cognitive screening assessments
Study: NCT06635005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an activity tracker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Undergo motivational interviews

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Participate in nutrition counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06634654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty is performed using conventional surgical techniques.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multifaceted diagnostic assessments
Description: Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-ups
Description: Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic screening
Description: Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
Study: NCT06001398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Acceptance and Commitment Therapy (PACT)
Description: PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
Study: NCT06621251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068 (calpurbatug), a human monoclonal antibody
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DAIR
Description: DAIR procedure will be performed between days 15-22
Study: NCT06696261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianxiaxiaopi Granules
Description: The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a simulated agent of Lianxiaxiaopi Granules
Description: The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
Study: NCT06701305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous injectable solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injectable solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Oral solution
Study: NCT06701942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple family group intervention therapy
Description: Overview The intervention will be implemented at designated clinics where adolescents living with HIV/AIDS (ALHIV) and their families currently receive care. These sites will provide the MFG intervention alongside standard care services. All eligible adolescents and their family members who consent to participate will be included in the intervention group.~Program Structure The MFG intervention consists of 16 structured sessions, each running for 90 minutes. Sessions will be scheduled to coincide with clinic days over a 14-week period to maximize accessibility and attendance. Parent peers and community health workers, trained by the research team, will facilitate these group sessions.~Session Format Sessions on the MFGT will begin with introducing participants to one another, the facilitators, and the program curriculum. Subsequent sessions will concentrate on areas such as respectful communication, support, resilience building, problem-solving, conflict resolution, stress management
Study: NCT06702306

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Surveillance
Description: Lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 and 12 months.
Study: NCT05860712

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Irrigation
Description: Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
Study: NCT05788237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF+qIRV
Description: RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV
Description: Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF + qIRV 1.0 mL formulation
Description: RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF + qIRV 1.0 mL formulation
Description: RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF + qIRV 0.5 mL formulation
Description: RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
Study: NCT06384365

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: The control and the athletic group differ in the degree of physical acitvity
Study: NCT05013749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Myometrial Resection
Description: Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
Study: NCT06323343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Intervention
Description: Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Webpage links
Description: Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
Study: NCT06419803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used in gestational diabetics to control blood glucose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used in gestational diabetics to control blood glucose levels
Study: NCT05698524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI 24781
Description: Patients will take the PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
Study: NCT06580184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEARN 2 Platform
Description: The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LEARN 2 Platform
Description: The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.
Study: NCT05657873

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: L-SABR
Description: L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-(L)1 based immunotherapy
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-(L)1 based immunotherapy
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Study: NCT05795062

Intervention type: DRUG
Intervention: apixaban
Description: patients treated with apixaban

Intervention type: DRUG
Intervention: warfarin
Description: patients treated with warfarin
Study: NCT05338437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Bilateral quadriceps muscle stimulation
Study: NCT04938063

Intervention type: OTHER
Intervention: Assessing the correlation between Functional Impairment and Parenting Stress
Description: Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
Study: NCT06107959

Intervention type: OTHER
Intervention: Pre-surgical nutrition, hydration, RMR, and body composition assessments
Description: Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.

Intervention type: OTHER
Intervention: Pre-surgical nutrition, hydration, RMR, and body composition assessments
Description: Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.

Intervention type: OTHER
Intervention: Post-surgical nutrition, hydration, RMR and body composition assessments
Description: Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.

Intervention type: OTHER
Intervention: Post-surgical nutrition, hydration, RMR and body composition assessments
Description: Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.